文献速递心力衰竭与心肌病

识别晚期心衰中庞大的门诊C2D阶段:行动呼吁

Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure-A Call to Action.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该文总结为期三天研讨会的发现,提出十个关键要点并建议目标研究队列,呼吁采取行动改善这一庞大门诊人群的结局。

要点

  • 门诊C2D心衰指已超出推荐C期治疗支柱但仍有有意义生存年的患者。
  • 国家数据库仅选择性捕获心脏移植或左心室辅助装置候选的小部分人群。
  • 需识别C2D心衰的生理表型(低心输出量、右心衰、心肾综合征等)以靶向治疗。

核心结论

  • 研讨会提出十个关键要点,并建议将目标队列研究作为关键下一步。
  • 该文呼吁解决知识缺口并制定新策略以改善门诊C2D心衰人群的结局。

研究设计与样本

  • 本文总结该研讨会的发现,聚焦门诊C2D心衰的知识缺口与研究优先方向。

主要发现

  • 晚期门诊心衰人群已超出推荐C期治疗支柱,但仍有有意义生存年。
  • 国家数据库仅选择性捕获被接受心脏移植列表或左心室辅助装置的小部分患者。
  • 其他门诊晚期心衰患者的流行病学、轨迹和治疗了解甚少。
  • 研讨会调查了C2D心衰识别、受影响人群规模与可识别亚群、以及生理表型等初始挑战。
  • 社会驱动因素和患者对生存质量/长度的偏好被视为个性化治疗的重要修饰因素。

关键数值与推荐

  • C2D阶段指门诊心衰患者有日常症状限制并向难治性终末期D期心衰过渡。
  • 生理表型包括低心输出量、右心衰、心肾综合征、淤血性肝病和衰弱。

临床怎么用

  • 临床应识别超出C期治疗支柱但仍有有意义生存年的门诊C2D心衰患者。
  • 评估低心输出量、右心衰、心肾综合征、淤血性肝病和衰弱等生理表型以指导治疗。
  • 考虑社会驱动因素和患者对生存质量/长度的偏好以个性化治疗。

局限性

  • 本文为研讨会总结,未报告原始研究数据或系统分析。
  • 国家数据库仅选择性捕获移植列表或左心室辅助装置患者,限制对其他门诊晚期心衰人群的了解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although these patients are commonly encountered in practice, national databases selectively capture the small groups accepted for heart transplant listing or left ventricular assist devices. The epidemiology, trajectories, and therapies for other ambulatory patients with advanced HF are poorly understood. OBSERVATIONS: In December 2022, the National Heart, Lung and Blood Institute convened a team of experts to identify knowledge gaps and research priorities for the ambulatory population with limiting daily symptoms and transition toward refractory end-stage D HF, designated as stage C2D. This article summarizes the findings from that 3-day workshop. Workshop participants surveyed the initial challenges and knowledge gaps for (1) recognition of ambulatory C2D HF, (2) estimation of the magnitude of the affected population and identifiable subpopulations, and (3) physiologic phenotypes, such as low cardiac output, right HF, cardiorenal syndromes, congestive hepatopathy and frailty, which offer distinct targets for existing and emerging therapies. Social drivers of HF and patient preferences for quality/length of survival were highlighted as essential modifiers for personalization of therapies. CONCLUSIONS AND RELEVANCE: Ten key points summarized workshop findings, with target cohorts for study proposed as a crucial next step. This workshop summary is intended as a call for action to address knowledge gaps and develop new strategies to improve outcomes in the large ambulatory population with C2D HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Dunlay, Pinney, Lala, et al. Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure-A Call to Action. JAMA Cardiol. 2025. PMID: 39908057. doi:10.1001/jamacardio.2024.5328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。